DK2076132T3 - P-toluensulfonsyresalt af 5-amino-3-(2´-o-acetyl-3´desoxy-beta-d-ribofuranosyl)-3h-thiazol[4,5-d]pyrimidin-2-on og fremgangsmåder til fremstilling deraf - Google Patents

P-toluensulfonsyresalt af 5-amino-3-(2´-o-acetyl-3´desoxy-beta-d-ribofuranosyl)-3h-thiazol[4,5-d]pyrimidin-2-on og fremgangsmåder til fremstilling deraf

Info

Publication number
DK2076132T3
DK2076132T3 DK07873546.1T DK07873546T DK2076132T3 DK 2076132 T3 DK2076132 T3 DK 2076132T3 DK 07873546 T DK07873546 T DK 07873546T DK 2076132 T3 DK2076132 T3 DK 2076132T3
Authority
DK
Denmark
Prior art keywords
desoxy
ribofuranosyl
pyrimidin
thiazole
acetyl
Prior art date
Application number
DK07873546.1T
Other languages
English (en)
Inventor
David Kucera
Gregory J Haley
Erik J Rueden
Tingman Wang
Martin Viertelhaus
Fritz Blatter
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2076132T3 publication Critical patent/DK2076132T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK07873546.1T 2006-10-17 2007-10-16 P-toluensulfonsyresalt af 5-amino-3-(2´-o-acetyl-3´desoxy-beta-d-ribofuranosyl)-3h-thiazol[4,5-d]pyrimidin-2-on og fremgangsmåder til fremstilling deraf DK2076132T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85200206P 2006-10-17 2006-10-17
US89940507P 2007-02-05 2007-02-05
US95359707P 2007-08-02 2007-08-02
PCT/US2007/081526 WO2008140549A1 (en) 2006-10-17 2007-10-16 P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-β-D-RIBOFURANOSYL)-3H-THIAZOLE [4, 5-D] PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION

Publications (1)

Publication Number Publication Date
DK2076132T3 true DK2076132T3 (da) 2012-09-10

Family

ID=39472747

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07873546.1T DK2076132T3 (da) 2006-10-17 2007-10-16 P-toluensulfonsyresalt af 5-amino-3-(2´-o-acetyl-3´desoxy-beta-d-ribofuranosyl)-3h-thiazol[4,5-d]pyrimidin-2-on og fremgangsmåder til fremstilling deraf

Country Status (24)

Country Link
US (2) US7928085B2 (da)
EP (1) EP2076132B1 (da)
JP (2) JP5279715B2 (da)
KR (2) KR101515077B1 (da)
AR (1) AR063484A1 (da)
AU (1) AU2007353381B2 (da)
BR (1) BRPI0717741A2 (da)
CA (2) CA2666537C (da)
CY (1) CY1113368T1 (da)
DK (1) DK2076132T3 (da)
DO (1) DOP2007000131A (da)
EA (1) EA017005B1 (da)
ES (1) ES2390930T3 (da)
IL (2) IL198180A (da)
MX (1) MX2009004028A (da)
MY (1) MY150408A (da)
NO (1) NO20091598L (da)
NZ (1) NZ576408A (da)
PE (1) PE20081105A1 (da)
PL (1) PL2076132T3 (da)
PT (1) PT2076132E (da)
TW (1) TWI415854B (da)
UY (1) UY30650A1 (da)
WO (1) WO2008140549A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101461604B1 (ko) 2006-06-22 2014-11-18 애나디스 파마슈티칼스, 인코포레이티드 5-아미노-3-(3''-데옥시-β-D-리보퓨라노실)-티아졸로[4,5-d]파이리미딘-2,7-다이온의 프로드럭
WO2009026292A1 (en) 2007-08-20 2009-02-26 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
SG11201704512PA (en) 2014-12-08 2017-07-28 Hoffmann La Roche 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
CA2979490C (en) 2015-03-16 2023-07-18 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
CN107743491B (zh) 2015-05-08 2020-08-21 豪夫迈·罗氏有限公司 用于治疗和预防病毒感染的新的氧硫杂环戊烷甲酸及其衍生物
JP6806709B2 (ja) 2015-05-12 2021-01-06 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ウイルス感染症の治療と予防のための新規置換アミノチアゾロピリミジンジオン
WO2017001307A1 (en) 2015-06-30 2017-01-05 F. Hoffmann-La Roche Ag Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
CA3048768A1 (en) 2017-01-06 2018-07-12 F. Hoffmann-La Roche Ag Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds
CN110007010A (zh) * 2018-01-05 2019-07-12 大鹏药品工业株式会社 源自曲氟尿苷的类似物质的检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07224081A (ja) * 1994-02-10 1995-08-22 Kobayashi Koryo Kk デオキシリボフラノシルハライド誘導体の製造方法
US5532374A (en) * 1995-06-06 1996-07-02 Hitachi Chemical Company, Ltd. Method of preparation of bis-quinolines
JP4067226B2 (ja) * 1999-04-01 2008-03-26 三井化学株式会社 1―ハロゲノ−2−デオキシリボフラノース誘導体の製造方法
JP2000327693A (ja) * 1999-05-21 2000-11-28 Mitsui Chemicals Inc 2’−デオキシ−β−シチジン誘導体の製造方法
US6649761B2 (en) * 2001-05-30 2003-11-18 Merck & Co., Inc. Process for preparing piperazinepentaneamide HIV protease inhibitors
AP2004003069A0 (en) * 2001-11-27 2004-06-30 Anadys Pharmaceuticals Inc 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
AU2003289995A1 (en) * 2002-12-09 2004-06-30 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
JP2007504232A (ja) * 2003-09-05 2007-03-01 アナディス ファーマシューティカルズ インク C型肝炎ウイルス感染治療用のtlr7リガンド及びそのプロドラッグの投与
CA2566541C (en) * 2004-06-07 2012-10-09 Anadys Pharmaceuticals, Inc. 3-.beta.-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof
US7560544B2 (en) * 2004-12-17 2009-07-14 Anadys Pharmaceuticals, Inc. 3,5-Disubsitituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
US7501526B2 (en) * 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
KR101461604B1 (ko) * 2006-06-22 2014-11-18 애나디스 파마슈티칼스, 인코포레이티드 5-아미노-3-(3''-데옥시-β-D-리보퓨라노실)-티아졸로[4,5-d]파이리미딘-2,7-다이온의 프로드럭
KR101266843B1 (ko) * 2006-12-08 2013-05-24 가부시키가이샤 에이피아이 코포레이션 퓨라노스 유도체의 제조방법

Also Published As

Publication number Publication date
MY150408A (en) 2014-01-15
KR101515077B1 (ko) 2015-04-24
EP2076132B1 (en) 2012-07-11
IL223126A0 (en) 2012-12-31
DOP2007000131A (es) 2008-09-15
EA200970387A1 (ru) 2009-10-30
TW200833699A (en) 2008-08-16
US20090197826A1 (en) 2009-08-06
MX2009004028A (es) 2009-05-11
BRPI0717741A2 (pt) 2014-04-08
NO20091598L (no) 2009-07-10
PE20081105A1 (es) 2008-08-15
TWI415854B (zh) 2013-11-21
KR20090074237A (ko) 2009-07-06
US20110172447A1 (en) 2011-07-14
CA2898225A1 (en) 2008-11-20
PL2076132T3 (pl) 2013-01-31
JP5279715B2 (ja) 2013-09-04
US8193342B2 (en) 2012-06-05
KR20140119203A (ko) 2014-10-08
WO2008140549A1 (en) 2008-11-20
EP2076132A4 (en) 2011-05-04
NZ576408A (en) 2012-04-27
HK1132429A1 (en) 2010-02-26
AU2007353381A1 (en) 2008-11-20
PT2076132E (pt) 2012-10-03
EP2076132A1 (en) 2009-07-08
IL223126A (en) 2016-08-31
AU2007353381B2 (en) 2013-07-04
KR101486444B1 (ko) 2015-01-26
JP5703334B2 (ja) 2015-04-15
AR063484A1 (es) 2009-01-28
IL198180A0 (en) 2009-12-24
CA2666537A1 (en) 2008-11-20
ES2390930T3 (es) 2012-11-19
EA017005B1 (ru) 2012-09-28
CY1113368T1 (el) 2016-06-22
UY30650A1 (es) 2008-05-31
CA2666537C (en) 2015-12-08
JP2013166782A (ja) 2013-08-29
JP2010506947A (ja) 2010-03-04
US7928085B2 (en) 2011-04-19
IL198180A (en) 2015-06-30

Similar Documents

Publication Publication Date Title
FIC20250005I1 (fi) Irinotekaanisukrosofaattisuola
DK2076132T3 (da) P-toluensulfonsyresalt af 5-amino-3-(2´-o-acetyl-3´desoxy-beta-d-ribofuranosyl)-3h-thiazol[4,5-d]pyrimidin-2-on og fremgangsmåder til fremstilling deraf
DK1993575T3 (da) Sammensætninger omfattende humane embryostamceller og derivater deraf, fremgangsmåder til anvendelse og fremgangsmåder til fremstilling
DK2032598T3 (da) Axmi-031, axmi-039, axmi-040 og axmi-049, en familie af deltaendotoksingener og fremgangsmåder til deres anvendelse
DE502006004368D1 (de) Wirbelsäulenimplantat
DK1698630T3 (da) Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
DK2101819T3 (da) Fremgangsmåder, sammensætninger og kits til behandling af smerte og pruritis
HUS1600048I1 (hu) Készítmény Fabry-kór kezelésére
DK3851447T3 (da) Fremgangsmåder, forbindelser, sammensætninger og vehikler til administration af 3-amino-1-propansulfonsyre
ATE467633T1 (de) 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung
DK2056845T3 (da) Struktur og anvendelse af 5'-phosphat-oligonukleotider
DK1799235T3 (da) Sammensætninger af fosterhudcelleprotein til behandling af hudtilstande, -lidelser eller -sygdomme og fremgangsmåder til fremstilling og anvendelse deraf
EP2049713A4 (en) tissue rejection
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
DE602004021940D1 (de) Endoskopsystem
DK2029799T3 (da) Termostabile proteiner og fremgangsmåder til fremstilling og anvendelse heraf
DK2019090T3 (da) Substitueret beta-phenyl-alfa-hydroxypropansyre, fremgangsmåde til syntese og anvendelse deraf
DK1937633T3 (da) Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme
PL1816116T3 (pl) Kompozycje chemiczne i sposoby ich wytwarzania
DK1813678T3 (da) Fremgangsmåde til fremstilling af glycogen
DK1948615T3 (da) Til behandling af gynækologiske sygdomme egnede pyrazolderivater
EP1940444A4 (en) PROCESS FOR THE PREPARATION OF TARGETED IMMUNOLIPOSOMES
EP1812368A4 (en) PROCESS FOR THE PREPARATION OF SEVOFLURANE
EP2155792A4 (en) PROTEIN G-OLIGONUCLEOTIDE CONJUGATE
DK2041069T3 (da) Benzylaminer, fremgangsmåde til fremstilling deraf og deres anvendelse som anti-inflammatoriske midler